732 results about "Nude mouse" patented technology

Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.

A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA / u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and / or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and / or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

The invention belongs to the technical field of tissue engineering and particularly relates to adipose tissue source exosome gel, a preparation method and application. The adipose tissue source exosome gel is characterized by comprising an adipose tissue exosome and a solvent in a mass-volume ratio of (1-3):1, wherein an aquogel is served as the solvent. The preparation method comprises the following steps: treating an adipose tissue, acquiring an adipose tissue extract, acquiring the adipose tissue source exosome and preparing the adipose tissue source exosome gel. The adipose tissue source exosome gel is mainly used for promoting the fat regeneration. The invention particularly relates to the exosome extracted from the adipose tissue. When the exosome is applied to the nude mouse body, a new mature adipose tissue can be generated. The defects of insufficient seed cell resource, potential malignant transformation and tumor formation of the traditional tissue engineering can be overcome; the exosome has the advantage of easiness in storage and transportation; a new thought is supplied for acquiring the fat for the tissue engineering.

The present invention relates to the gromwell naphthoquinone derivative and its application in preparing anticancer medicine. Experiment shows that the gromwell naphthoquinone derivative has obvious inhibition to tumor cell strain CNE2, Glc-82, S180A, EAC, HepA, etc, and the research on nude mouse transplantation tumor model of human cancer cell also proves the anticancer action of the gromwell naphthaquinone derivative.

The invention belongs to the field of pharmacy and relates to a D-configuration polypeptide and a gene delivery system of the D-configuration polypeptide and particularly relates to the D-configuration polypeptide which has high combining activity with neuropilin NRP-1 and has the brain tumor targeting and tumor tissue penetrating capabilities. The D-configuration polypeptide provided by the invention can mediate a nano delivery system to deliver drugs to tumors in a targeted manner for realizing targeted treatment of brain in-situ glioma. In vivo and in vitro experiments show that the genetic vector modified by the D-configuration polypeptide can remarkably improve the gene transfection efficiency. The genetic vector entrapping the therapeutic gene pORF-hTRAIL can remarkably prolong the lifetime of a nude mouse of brain glioma in-situ mode.

A liver cancer blood vessel specific target polypeptide LCI-X7 able to specific binding with liver cancer blood vessel is extracted from the naked mouse model of human liver cancer by the showing technique of phage random peptide library in body and microscopic laser cutting technique. It provides important theory and practical basis for the diagnosis to liver cancer transfer recurrence and target therapy.

The invention discloses a preparation method of a barley extract fermented by lactobacillus and an anti-tumor effect of the barley extract fermented by lactobacillus, belonging to the field of food biotechnology. Lactobacillus plantarum (lactobacillus plantarum Dy-1, CGMCC No.6016) is screened from pickled vegetables to serve as a fermentation strain for fermenting the barley, and fermentation conditions are controlled, so that the extract of fermented barley is obtained. Cell tests indicate that the extract has obvious effects on promoting apoptosis and suppressing multiplication of human colon cancer HT-29 cells and gastric cancer SGC-7901 cells, and a model test of the nude mouse bearing the tumor with the human colon cancer HT-29 indicates that the extract has obvious effects on suppressing tumor growth and improving the immune activity of the nude mouse bearing the tumor. According to the preparation method of the barley extract fermented by lactobacillus, the barley is pretreated simply and the production cost is low; and direct vat set fermentation is employed, so that the preparation method of the barley extract fermented by lactobacillus is convenient and rapid, safe and stable, and convenient to control the quality.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.

The invention discloses a pro-drug as shown in general formula (I), which is formed by coupling camptothecin or a derivative of the camptothecin with non-linear configuration glycol polyethylene, wherein, the definition for varied groups is available in the specification. A physiological disposition research on nude mice discloses that: the pro-drug has a time-delay plasma concentration - time curve, and the plasma concentration can still be maintained at over 100ng / ml 72 hours after intravenous medication. Evaluation on physiological drug effect shows that the pro-drug has strong growth inhibiting effect against the LOVO HCT116 cell line transplantable tumor inoculated into the nude mice and also has obvious growth inhibitory activity against human lung carcinoma H460 cell line transportable tumor inoculated into the nude mice. The inhibition of the pro-drug is better than that of Irinotecan, a positive control drug and has no obvious systemic toxicity.

The invention belongs to microbiological animal cell system fiels, which in detail relates to a pancreatic cancer hepatic metastases clone SW1990HM with hepatic metastases potence. The clone possesses special transition phenotype, and if inoculated to mouse spleen, it will result to 100% hepatic metastases, and it is the first human pancreatic cancer clone with hepatic metastases potence in domestic. The genetic backgroud of said clone strain is the same to that of origianl cell, and it is characterized by strong invasiveness, high transmission efficiency and large transmission range. The invention provides proper experimental platform for further researching, preventing and treating pancreatic cancer hepatic metastases.

The invention discloses a tumor targeted living body rapid fluorescence imaging method of a rare earth metal nanocluster. According to the invention, a rare earth metal salt solution of certain concentration and different tumor cells are incubated under physiological conditions for in situ synthesis of the rare earth metal nanocluster, thus realizing real-time, high resolution fluorescence imaging of tumor cells. The rare earth metal nanocluster provided in the invention realizes fast and real-time in situ living tumor targeted fluorescence imaging on a transplant tumor nude mouse model. The rare earth metal nanocluster involved in the invention is biosynthesized directly through tumor cells, and has very good biocompatibility. The in situ living body fluorescence imaging method provided in the invention realizes fast and accurate positioning and tumor targeted imaging analysis, thus having wide medical application prospects.

A use of PD-0332991 in preparation of drugs preventing and treating drug-resistant tumor is disclosed. Application of a cell biological method and a molecular biological method and human gefitinib-resistant nude-mouse transplanted tumor model tests prove that: the PD-0332991 can effectively inhibit growth of human gefitinib-resistant lung cancer cells, induce apoptosis, regulate and control cell cycle related gene, cause tumor cell cycle arrest and induce apoptosis. Accordingly, the PD-0332991 can be adopted as an effective component for preparation of drugs preventing and treating gefitinib-resistant tumor, and foods, health products and cosmetics for preventing and treating drug-resistant tumor.

The invention discloses a regulating method of a WDR63 gene in osteogenic differentiation and odontogenicdifferentiation processes of a mesenchymal stem cell. The cell is replanted by virtue of cell culture, chromatin immunoprecipitation reaction and data analysis, plasmid construction and virus infection, western blotting analysis, cell reproductive capacity determination and alkaline phosphatase and alizarin red dyeing subcutaneously of a nude mouse, and the regulating effect of the WDR63 gene in osteogenic differentiation and odontogenic differentiation processes of the mesenchymal stem cell and the effect of promoting regeneration of tooth tissues are found. By virtue of the adjusting effect of gene activity and function of the mesenchymal stem cell by trimethylation of lysine on the fourth site of histone 3, the regulating effect of the WDR63 gene in osteogenic differentiation and odontogenicdifferentiation processes of the mesenchymal stem cell and the effect of the WDR63 gene in promoting regeneration of tooth tissues, the WDR63 gene obtained probably has a promoting effect on osteogenic differentiation of stem cells from apical papilla.

The invention discloses application of silver and platinum nano-cluster in tumor targeted imaging. The application comprises the following steps: establishing nude mice tumor model; locally injecting ultrasonically dispersed silver or platinum nano-cluster into the nude mice, or directly injecting 0.1-100mu mol / L silver- or platinum-containing solution; medically imaging the nude mice tumor part by using a medical imaging method and performing qualitative and quantitative analysis on the imaging result after injection within 24 hours. The prepared silver and platinum nano-cluster is small in particle size, high in permeability, high in fluorescence stability, high in sensitivity and high in targeting property, and the tumor can be accurately positioned; the silver and platinum nano-cluster is directly synthesized through organisms and has high biocompatibility; the silver and platinum nano-cluster is injected through ultrasonic dispersion, so that the nano particles are fine and uniform, and absorption is facilitated; and moreover, the application is convenient to operate and intuitive in result.

The invention relates to a bispecific oligopeptide-lidamycin energized fusion protein Ec-LDP-Hr-AE. The fusion protein comprises two oligopeptides of targeted epidermal growth factor receptors EGFR and HER2, a lidamycin apoprotein and a lidamycin activity chromophore, and researches show that the fusion protein in vitro can be combined with the epidermal growth factor receptors EGFR and HER2 for expressing the specificities of the tumor cells, has strong damaging effect for the tumor cells and remarkable therapeutic effect for the transplanted tumor of nude mice for the ovarian cancer SK-OV-3 after the in vivo test, displays the characteristics of miniaturization and high efficiency of targeting drugs and has good application prospect.

The invention provides berbamine citrate. Berbamine free alkali is taken as a raw material, and edible strong organic acid is applied to substitute the prior commonly-used inorganic acid to perform a salt-forming reaction according to certain proportion at room temperature to obtain the berbamine citrate. The berbamine citrate has remarkable killing effect on various hematological tumor cells cultured in vitro such as human leukemia, multiple myeloma, lymphoma and so on, and also has remarkable inhibition effect on the growth of human hematological tumor cells in the bodies of nude mice, but the berbamine citrate with the same concentration has no remarkable effect on the cell growth of normal persons and has no remarkable toxic side effect on the nude rice; and the berbamine citrate can form a pharmaceutical composition with other optional known anti-tumor medicines with one or more therapeutically effective amounts to achieve the synergistic effect. Therefore, the berbamine citrate can be applied to the preparation of medicines for treating hematological tumor diseases.

Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.

Methods are disclosed for treating neoplastic disorders, such as pancreatic cancer, using tocotrienols; namely, gamma-tocotrienol and delta tocotrienol. The antitumorogenic effects of these compounds are shown both in vitro and in vivo using several human pancreatic cancer cell lines and MIA-PACA2 human pancreatic cancer cells xenografted in nude mice. Also disclosed are methods of testing the efficacy of potential chemotherapeutic agents by measuring their effect on surrogate endpoint biomarkers, such as Ki-67 and p27. Associated compounds are also disclosed.

The invention relates to a three-dimensional culture system based on thermo-sensitive biogel. The three-dimensional culture system is prepared by combining the following reagents: thermo-sensitive biogel, digestive fluid required for separating and culturing tumor cells, a basal culture medium and a human intestinal stem cell culture medium. The invention also provides a method for establishing acolorectal cancer patient-derived xenograft model through the three-dimensional culture system based on thermo-sensitive biogel. The three-dimensional culture system has the advantages that colorectalcancer cells can be further amplified and grown in the three-dimensional culture system based on thermo-sensitive biogel, and the tumor formation capability of the colorectal cancer cells in the immune deficient mice can be enhanced. Polyclonal tumor cells cultured in the system have high subcutaneous tumor formation capability in nude mice. The three-dimensional culture system has the advantagesof simple preparation method and mature technology, and is capable of greatly reducing the time and the cost for establishing the human-derived colorectal cancer xenograft model.

The invention discloses a method for preparing a PLGA slow-release microsphere carrying docetaxel and an application thereof in the chemotherapy of the mesenchyma stroma of tumors under ultrasonic mediation. The PLGA slow-release microsphere carrying the docetaxel is a medicine-carrying microsphere prepared from PLGA and the docetaxel by a single emulsification method, the molecular weight of the PLGA in the medicine-carrying microsphere is 5000-50000dal, the mole ratio of lactic acid to glycollic acid is 75:25-50:50, the feeding ratio of the PLGA to the docetaxel is 100 / 1-100 / 10, and the PLGA slow-release microsphere carrying the docetaxel is prepared by emulsification in an organic solvent. The slow-release microsphere preparation carrying the docetaxel is injected into the tumor tissues of nude mice with human liver cancer, beast cancer and ovarian cancer, and the necrosis situation of the tumors is checked by pathological histology; the result shows that the slow-release microsphere carrying the docetaxel can thoroughly ablate and inactivate the tumors, reduces the whole-body toxic or side effect of the medicine obviously and is a novel method for the chemotherapy of the mesenchyma stroma of the tumors under ultrasonic intervention with very good clinical application prospect.

The invention relates to a method for obtaining tissue engineering cartilage through directionally inducing bone-marrow mesenchymal stem cells (BMSCs). At present, a large amount of exogenous growth factors and culture in vitro are needed before culturing the BMSCs and the cartilage cells in vivo to promote the differentiation of the BMSCs towards the cartilage cells. The method comprises the following steps of: mixing the sub-cultured P3-generation BMSCs, the cartilage cells and a large extracellular matrix aggregate (cell brick), resuspending the mixture into a platelet rich plasma to prepare a cell compound of the sub-cultured P3-generation BMSCs, the cell brick and the platelet rich plasma, injecting the compound into the skin on the back of a nude mice when the compound condenses gradually, and culturing to obtain the new tissue engineering cartilage. The completely biological and injectable tissue engineering cartilage is obtained on the basis of coculturing the BMSCs and the cartilage cells. The differentiation of the BMSCs towards the cartilage cells can be kept stably, the hypertrophy of the tissue engineering cartilage in vivo can be inhibited effectively, and the defects in the background art can be overcome.

The invention discloses a traditional Chinese medicine composition for treating gastric cancer. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of pilose asiabell root, 15-35 parts of fresh rhizoma atractylodis macrocephalae, 10-20 parts of zedoary, 10-15 parts of rhizoma pinelliae preparata, 10-30 parts of Chinese actinidia root and 10-30 parts of rhodiola rosea. The traditional Chinese medicine composition exerts advantages of comprehensive therapy of traditional Chinese medicine, and dialectics is combined with differentiation of disease; and according to etiology, pathogenesis and pathology features of gastric cancer, experimental observation on an in-vitro experiment for inhibiting gastric cancer SGC7901 cell proliferation by medicines and an in-vivo experiment for inhibiting transplanted tumor of gastric cancer SGC7901 cells in nude mice by medicines shows that the traditional Chinese medicine composition in the invention can induce the SGC7901 cells to produce autophagy so as to inhibit the proliferation of the gastric cancer SGC7901 cells, thereby opening a road for hope for treating patients with gastric cancer.

The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL / lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

The invention relates to a long-chain non-coding RNA IncRNA-BcrAR and application thereof in cell canceration resistance. IncRNA-BcrAR is in low-level expression in a human chronic myelogenous leukemia cell line K562 with positive Bcr-Abl, the K562 cell line with overexpressed IncRNA-BcrAR is constructed, the action of IncRNA-BcrAR on Bcr-Abl induced cell neoplastic transformation is observed, experiments prove that the IncRNA-BcrAR overexpression can obviously promote K562 cell apoptosis induced by Imatinib (therapeutic drug of Abl positive leukemia patients) and can remarkably inhibit tumor growth induced by K562 cells in a naked mouse body; and besides, the IncRNA-BcrAR overexpression can remarkably promote A-MuLV transformed mouse leukemia cell BC44 apoptosis induced by Imatinib. The IncRNA-BcrAR has important effect on Bcr-Abl and v-Abl mediated cell canceration resistance, and the long-chain non-coding RNA IncRNA-BcrAR provides new molecular marker and drug target for diagnosis and treatment of Abl induced leukemia.

The invention belongs to the field of microorganism animal cell system, and relates to an establishment method of a fluorescence visualization human hepatoma nude mice model which can self emit high strength red or green fluorescences and has the metastatic ability. After obtaining a human high-metastatic fluorescence hepatoma cell line HCCLM3-R, HCCLM3-G, HCCLM6-R and HCCLM6-G of fluorescence genes with high chromosome conformable degree, high fluorescence intensity and stable expression by using the method of pseudotype slow virus infection, hepatoma cells expressed by the fluorescences is placed beneath nude mice skin to establish a fluorescence visualization high-metastatic human hepatoma nude mice subcutaneous tumor model or subcutaneous fluorescence expression tumor tissues is placed in nude mice hepar to establish a fluorescence visualization high-metastatic human hepatoma nude mice hepar primary tumor model. The got model can be used as a tracer of animal in vivo hepatoma cells, and can be used for molecular mechanism study of hepatoma recurrence and metastatic and prophase therapeutic effect discrimination for new anti-hepatoma therapy and new anti-hepatoma drugs, etc.

Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SDl and SD2, human single-domain antibodies to mesothelin. SDl recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SDl as a potential therapeutic agent, a recombinant human Fc (SDl-hFc) fusion protein was generated. The SDl-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody- dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SDl-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SDl and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.

The invention belongs to the biological medicine field, and discloses a targeted boron preparation and a preparation method and application. The target boron preparation comprises polyamidoamine-amine dendrimers, epidermal growth factor receptor antibody and polyhedral boranes, the polyamide amine dendrimers are connected with the epidermal growth factor receptor antibody, and are internally loaded with the polyhedral boranes. The targeted boron preparation is high in boron content, can meet the requirements of BNCT (boron neutron capture therapy) on the boron atom dose, is well targeted to tumor cells, has good stability and low cell toxicity, and can be efficiently uptaken by human glioma U87MG cells of high surface expression EGFR (epidermal growth factor receptor). The target boron preparation can effectively improve the content of boron in orthotopic transplantation tumor nude mice tumor tissues, can significantly prolong orthotopic transplantation tumor nude mice lifetime by neutron irradiation, and is suitable for boron neutron capture therapy for glioma. The preparation method of the targeted boron preparation has the advantages of simple operation, and the prepared targeted boron preparation has good stability.

The invention discloses a new medical application of oleanolic acid in cervical cancer resistance, and also discloses clinically acceptable pharmaceutical preparations such as tables, capsules, pills, injections and the like which are prepared by using oleanolic acid as a pharmaceutical raw material. The oleanolic acid pharmaceutical preparation of the present invention comprises 1%-99% of oleanolic acids and 99%-1% medicinal excipients (including other compatible drugs). The oleanolic acid and the pharmaceutical preparations thereof provided by the invention have an excellent anti-cervical cancer effect which is represented by significant inhibitory activity against in vitro human cervical cancer cells and significant tumor inhibitory activity against a transplanted tumor in nude mice of the cancer cell. In addition, the active components of the pharmaceutical preparation are traditional Chinese medicine extracts, so the preparation has the advantage of less toxic and side effect than chemotherapeutic drugs.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.